Ozanimod

Lexicon Strengthens Management Team With Two New Executives

Retrieved on: 
Tuesday, October 31, 2023

THE WOODLANDS, Texas, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Matthew Cullen is joining the company as vice president of value and access, effective November 1, 2023, and Lisa DeFrancesco will join as head of investor relations and corporate strategy, effective November 13, 2023.

Key Points: 
  • Mr. Cullen brings Lexicon more than 35 years of industry experience in market access and sales leadership.
  • Before joining Lexicon, Matt served as vice president, value, access and policy at Apellis Pharmaceuticals where he led the market access launch of rare disease drug EMPAVELI® (pegcetacoplan) and ophthalmology drug SYFOVRE® (pegcetacoplan injection).
  • His responsibilities included pricing and contracting, payer strategy and marketing, corporate and strategic account management, field reimbursement, trade and distribution, and training.
  • Prior to Apellis, Mr. Cullen led strategic payer marketing and access teams at Bristol-Myers Squibb for ELIQUIS® (apixaban) and ORENCIA® (abatacept).

Bristol Myers Squibb Presents New Zeposia (ozanimod) Data on Long-Term Disease Progression and Cognition in Patients with Relapsing Forms of Multiple Sclerosis

Retrieved on: 
Wednesday, October 11, 2023

Bristol Myers Squibb (NYSE: BMY) today announced new data showing that after eight years of follow-up, 76% of patients treated with Zeposia for relapsing multiple sclerosis (RMS) were free of six-month confirmed disability progression (CDP).

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced new data showing that after eight years of follow-up, 76% of patients treated with Zeposia for relapsing multiple sclerosis (RMS) were free of six-month confirmed disability progression (CDP).
  • Findings also demonstrated treatment with Zeposia resulted in low rates of progression independent relapse activity (PIRA) and relapse-associated worsening (RAW), key drivers of disease progression and permanent disability in multiple sclerosis.
  • “These new data underscore Zeposia’s potential to delay disease progression and improve cognitive function, especially in individuals with early relapsing multiple sclerosis,” said Roland Chen, MD , senior vice president and head, Immunology, Cardiovascular and Neuroscience Development, Bristol Myers Squibb.
  • “With our focus on transformational science, we remain deeply committed to finding solutions to elevate care for the multiple sclerosis community.”
    Bristol Myers Squibb thanks the patients and investigators who participated in the Zeposia clinical trials.

Bristol Myers Squibb Launches Supporting You with UC, with Women’s World Cup Commentator, Former Professional Soccer Player and Ulcerative Colitis Patient, Rosie White

Retrieved on: 
Wednesday, July 12, 2023

Bristol Myers Squibb (NYSE: BMY) has launched Supporting You with UC, an ulcerative colitis (UC) educational campaign with patient ambassador* Rosie White.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) has launched Supporting You with UC, an ulcerative colitis (UC) educational campaign with patient ambassador* Rosie White.
  • “Our aim is for people with ulcerative colitis to have support that helps them navigate their illness,” explained Michael Braun, senior vice president, U.S. Immunology, Bristol Myers Squibb.
  • “We hope patients find inspiration in Rosie’s story and feel empowered to share their experiences and advocate for themselves to better manage their disease.”
    To learn more, visit www.SupportingYouwithUC.com .
  • *Rosie White is an actual Zeposia® patient who was compensated by Bristol Myers Squibb for her time.

Ulcerative Colitis Treatment Market to Grow Exponentially by 2029- Brandessence Market Research

Retrieved on: 
Thursday, May 18, 2023

The Global Ulcerative Colitis Treatment Market report curated by Brandessence Market Research provides a detailed overview of the market, including its size, growth rate, and key drivers.

Key Points: 
  • The Global Ulcerative Colitis Treatment Market report curated by Brandessence Market Research provides a detailed overview of the market, including its size, growth rate, and key drivers.
  • It examines various treatment options available for ulcerative colitis, including medications, surgery, and other therapies.
  • High Cost of Treatment: One of the major challenges in the ulcerative colitis treatment market is the high cost associated with the available treatment options.
  • FMT is being explored as a potential treatment option for ulcerative colitis, with ongoing clinical trials assessing its safety and efficacy.

Ulcerative Colitis Treatment Market to Grow Exponentially by 2029- Brandessence Market Research

Retrieved on: 
Thursday, May 18, 2023

The Global Ulcerative Colitis Treatment Market report curated by Brandessence Market Research provides a detailed overview of the market, including its size, growth rate, and key drivers.

Key Points: 
  • The Global Ulcerative Colitis Treatment Market report curated by Brandessence Market Research provides a detailed overview of the market, including its size, growth rate, and key drivers.
  • It examines various treatment options available for ulcerative colitis, including medications, surgery, and other therapies.
  • High Cost of Treatment: One of the major challenges in the ulcerative colitis treatment market is the high cost associated with the available treatment options.
  • FMT is being explored as a potential treatment option for ulcerative colitis, with ongoing clinical trials assessing its safety and efficacy.

Optic Nerve Disorder Treatment Market to Reach USD 5.3 Billion, Globally, by 2031 at 4.5% CAGR: Allied Market Research

Retrieved on: 
Monday, February 27, 2023

PORTLAND, Ore., Feb. 27, 2023 /PRNewswire/ -- Allied Market Research published a report, titled, "Optic Nerve Disorder Treatment Market by Treatment Type (Steroidal Therapy, Immunomodulators Therapy, Others Treatment Type), by Indication (Optic Neuritis, Glaucoma, Optic Nerve Atrophy, Others), by Distribution Channel (Hospital Pharmacies, Drug Stores, Retail Pharmacies, Online Providers): Global Opportunity Analysis and Industry Forecast, 2021-2031." According to the report, the global optic nerve disorder treatment industry generated $3,372.46 million in 2021, and is estimated to reach $5,247.82 million by 2031, witnessing a CAGR of 4.5% from 2022 to 2031. The report offers a detailed analysis of changing market trends, top segments, key investment pockets, value chains, regional landscapes, and competitive scenarios.

Key Points: 
  • Increase in prevalence of optic nerve disorder treatment, growth in geriatric population and increase in technological advancement drive the growth of the global optic nerve disorder treatment market.
  • PORTLAND, Ore., Feb. 27, 2023 /PRNewswire/ -- Allied Market Research published a report, titled, " Optic Nerve Disorder Treatment Market by Treatment Type (Steroidal Therapy, Immunomodulators Therapy, Others Treatment Type), by Indication (Optic Neuritis, Glaucoma, Optic Nerve Atrophy, Others), by Distribution Channel (Hospital Pharmacies, Drug Stores, Retail Pharmacies, Online Providers): Global Opportunity Analysis and Industry Forecast, 2021-2031."
  • According to the report, the global optic nerve disorder treatment industry generated $3,372.46 million in 2021, and is estimated to reach $5,247.82 million by 2031, witnessing a CAGR of 4.5% from 2022 to 2031.
  • Impact of Covid-19 on Optic Nerve Disorder Treatment Market:
    Decrease in the demand for optic nerve treatment due to the risk of Covid-19 infection had a negative impact on the global optic nerve disorder treatment market, especially during the lockdown period.

Can BMS' Zeposia Cement a Defensible Market Position in Ulcerative Colitis Ahead of Pfizer's Potential Rival S1P treatment, etrasimod? According to Spherix Global Insights

Retrieved on: 
Thursday, February 9, 2023

EXTON, Pa., Feb. 9, 2023 /PRNewswire/ -- Analysis from Spherix Global Insights quarterly market tracker, RealTime Dynamix™: Ulcerative Colitis, reveals that at twenty (20) months after the FDA approved Zeposia for use in Ulcerative Colitis (UC), stated physician use of the therapy remains low. A retrospective analysis across Spherix services suggests the drug has yet to cement a clear position which physicians commonly view as appropriate for the management of their UC patients.

Key Points: 
  • Zeposia is the only oral therapy indicated for the treatment of UC, which does not include a black box in its label.
  • That distinction gives it an advantage over the JAK class of medications, including Pfizer's Xeljanz (tofacitinib) and AbbVie's more recently launched Rinvoq (upadacitinib).
  • It is an advantage that affords Zeposia the opportunity to be prescribed in a first-line position ahead of biologics following an inadequate response to conventional systemic agents.
  • Despite this edge, physicians report prescribing Zeposia most often as a second or later line therapy, with its greatest proportion in third-line.

BMS' Zeposia and AbbVie's Skyrizi Shake Up First-Line Prescribing Patterns in the US Ulcerative Colitis and Crohn's Disease Markets, Spherix Reports

Retrieved on: 
Wednesday, November 30, 2022

EXTON, Pa., Nov. 30, 2022 /PRNewswire/ -- US gastroenterologists estimate that just under 60% of their ulcerative colitis (UC) and 55% of their Crohn's disease (CD) patients treated with a biologic or small molecule are on their first-line advanced systemic therapy. Over the past eighteen months, the US inflammatory bowel disease (IBD) market has become increasingly competitive with the market entry of BMS' Zeposia and AbbVie's Rinvoq for the treatment of UC and AbbVie's Skyrizi in CD, which have had material changes to new start IBD treatment patterns.

Key Points: 
  • Spherix Global Insights ("Spherix") has been tracking the newly initiated IBD patient segment for the past five years via their RealWorld Dynamix service .
  • When specifically examining UC new starts, Zeposia, a first-in-class S1P receptor modulator, has made substantial inroads as a pre-biologic option, capturing a sizeable portion of first-line patients.
  • Unsurprisingly, the most prominent driver behind Zeposia use is the brand's oral administration, followed by the perceived efficacy and unique MOA.
  • Crohn's disease new start patterns have also been altered by the newest CD market entrant, Skyrizi.

AbbVie's Humira Safety Net in Inflammatory Bowel Disease is Coming Through Strong, Creating New Threats to Existing Competitors, According to Spherix Global Insights

Retrieved on: 
Thursday, October 6, 2022

EXTON, Pa., Oct. 6, 2022 /PRNewswire/ -- Over the course of this year, AbbVie has proven successful in expanding their immunology portfolio to offset potential Humira losses with the impending launch of adalimumab biosimilars in January of 2023. Specifically, the Chicago-based manufacturer has scored recent FDA approvals of their JAK inhibitor, Rinvoq, for the treatment of ulcerative colitis (UC) and of their IL-23 inhibitor, Skyrizi, for the treatment of Crohn's disease (CD).

Key Points: 
  • Spherix recently surveyed over 75 US gastroenterologists on their current use and perceptions of the newest inflammatory bowel disease (IBD) market entrants through their Launch Dynamix services, including the impact on existing brands in the treatment landscape.
  • Perhaps more impressive is patient share projections, with Rinvoq's piece of the pie expected to quadruple by February of next year.
  • Coupled with Rinvoq's adoption, BMS' recently launched oral Zeposia is expected to make small but significant gains over the same time period.
  • According to one respondent, "[Rinvoq] is a drug now that has a different mechanism of action for ulcerative colitis.

New IBD Mechanisms of Action Are Poised to Gain EU5 Patient Switches as Anti-TNF Therapy Efficacy Fades in Ulcerative Colitis and Crohn's Disease, According to Spherix Global Insights

Retrieved on: 
Tuesday, August 16, 2022

EXTON, Pa., Aug. 16, 2022 /PRNewswire/ -- According to the latest report published as part of Spherix's RealWorld Dynamix™: Biologic/Small Molecule Switching in IBD (EU) service, EU gastroenterologists (n=285) have accelerated their switching of ulcerative colitis (UC) and Crohn's disease (CD) patients from anti-TNF therapies to treatments that include new pathways such as IL12/IL23 inhibition, α4β7 integrin binding, JAK inhibition, and S1P modulation.The Spherix study includes 1,280 unique IBD patient records from the EU5 (France, Germany, Italy, Spain, and the UK) that encapsulate patient-level data.

Key Points: 
  • The report also identifies a significant level of opportunity that still exists for new pathways and agents in IBD.
  • More specifically, 27% of UC patients and 30% of CD patients who have recently switched did so because of secondary efficacy failure.
  • The biosimilar therapies (infliximab and adalimumab) are the two treatment options most likely to trigger an efficacy-based switch.
  • In fact, when combining biosimilars and brands, TNF therapy represents the switch-from agent for a majority of all UC and CD patients.